Table 5.
Costs in the 4 weeks after index stratified by age, risk of severe COVID-19 and immunocompromised status at baseline among the primary care cohort
| Costs | All (n=1 693 263) |
Age stratifications | Risk criteria | Immunocompromised status at baseline | ||||
| 18–49 (n=1 161 843) |
50–64 (n=379 528) |
65–74 (n=92 573) |
75–84 (n=40 481) |
≥85 (n=18 838) |
Green Book (n=212 556) |
Immunocompromised (n=63 547) |
||
| Medication cost (£) | ||||||||
| Mean (SD) | 165 (465) | 242 (538) | 204 (505) | 134 (447) | 187 (530) | 8 (36) | 161 (448) | 486 (759) |
| Median (Q1, Q3) | 2 (2, 4) | 3 (2, 256) | 2 (2, 24) | 2 (2, 3) | 3 (1, 10) | 3 (1, 3) | 3 (2, 9) | 21 (3, 566) |
| Primary care consultations—F2F (£) | ||||||||
| Mean (SD) | 27 (22) | 26 (21) | 28 (22) | 27 (24) | 27 (25) | 27 (24) | 28 (25) | 28 (25) |
| Median (Q1, Q3) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) | 39 (7, 39) |
| Primary care consultations—telephone (£) | ||||||||
| Mean (SD) | 18 (10) | 17 (9) | 18 (10) | 18 (10) | 19 (11) | 20 (13) | 19 (11) | 18 (10) |
| Median (Q1, Q3) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) | 16 (16, 16) |
F2F, face to face.